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muscarinic receptors; vasodilation; genetically altered mice ACETYLCHOLINE IS A POWERFUL dilator of most vascular beds and a major diagnostic and investigative tool for the assessment of endothelial function (15, 24, 42) . Its activity is mediated by endothelial muscarinic receptors triggering the release of the actual vasorelaxing agents, such as nitric oxide (NO) (19, 26) . Five muscarinic receptor subtypes, M 1 -M 5 , have been identified (9) . They are generally grouped according to their preferential functional coupling, either to the mobilization of intracellular calcium via activation of phospholipase C␤ (M 1 , M 3 , M 5 ) or to the inhibition of adenylyl cyclase (M 2 , M 4 ) (45) . The odd-numbered muscarinic receptor subtypes (M 1 , M 3 , and M 5 ) have been reported to mediate endothelium-dependent vasodilation. Based on pharmacological studies making use of subtypepreferring agents, the M 1 receptor was suggested to be involved in cholinergic vasorelaxation of rat carotid arteries, the perforating branch of the human internal mammary artery, and human pulmonary and canine lingual arteries (10, 29, 32, 36) . Other classical pharmacological studies as well as functional studies in gene-targeted mice lacking specific muscarinic acetylcholine receptor subtypes demonstrated that the M 3 receptor mediates cholinergic vasodilation in various conduit vessels, such as the aorta and the femoral artery, and in some resistance vessels, such as coronary and ophthalmic arteries (2-3, 16, 20, 25) . One particularly striking observation was that the M 5 receptor mediated cholinergic responses in cerebral vessels from humans, cattle, and mice (13, 46) . Based on these findings, distinct muscarinic receptors may represent attractive therapeutic targets for the treatment of local ischemic disorders. Hence, it is important to clearly define the functional role of individual muscarinic receptor subtypes in the major vascular resistance beds considerably contributing to the systemic cardiovascular side effects, e.g., hypotension and flushing, encountered during the application of nonselective cholinergic agonists. Therefore, the goal of the present study was to examine the hypothesis that M 1 , M 3 , and M 5 receptors contribute to acetylcholine-induced vasodilation in small arteries from different vascular beds.
Because conclusions regarding the physiological role of individual muscarinic receptor subtypes are limited by the low selectivity of pharmacological agonists and antagonists, we used M 1 , M 3 , and M 5 receptor knockout mice (M1R Ϫ/Ϫ , M3R Ϫ/Ϫ , and M5R Ϫ/Ϫ mice, respectively) to perform functional studies in cutaneous, skeletal muscle, and renal interlobar arteries, all vessels from vascular beds substantially contributing to the control of systemic vascular resistance (18) .
MATERIALS AND METHODS

Animals. The generation of M1R
Ϫ/Ϫ , M3R Ϫ/Ϫ , and M5R
Ϫ/Ϫ mice has been described previously (17, 46 -47 Real-time PCR analysis in isolated arteries. Muscarinic receptor gene expression was quantified in isolated cutaneous, skeletal muscle, and renal interlobar arteries using real-time PCR. Mice were killed by CO 2 inhalation. Next, the kidneys, the hindlimbs, and a proximal segment of the tail were immediately removed and placed in ice-cold PBS solution (Invitrogen, Karlsruhe, Germany). Small cutaneous arteries from the tail, arteries from the gracilis muscle, and renal interlobar arteries were carefully isolated by using fine-point tweezers under a dissecting microscope, transferred to a 1.5-ml tube, and immediately snap-frozen. Subsequently, vessels were homogenized in lysis buffer using a homogenizing device (T10 basic Ultra-Turrax; IKA, Staufen, Germany). After homogenization, total RNA was extracted with a kit (RNeasy Micro Kit; Qiagen, Hilden, Germany) according to the manufacturer's protocol. After complete DNA digestion, the RNA was reverse transcribed with the use of an RT-PCR kit [High Capacity cDNA Reverse Transcription Kit (no. 4368814), RNase Inhibitor (no. N8080119); Applied Biosystems, Darmstadt, Germany] and random hexamers. Quantitative PCR analysis was performed (GeneAmp StepOne Plus; Applied Biosystems, Darmstadt, Germany). Nucleic acid stain (SYBR Green; Bioline, Luckenwalde, Germany) was used for the fluorescent detection of DNA generated during PCR. The PCR reaction was performed in a total volume of 12.5 l with 0.4 pmol/l of each primer and 2ϫ ready-to-use master mix (ImmoMix, BIO-25020; Bioline); 2 l cDNA were used as template. Published sequences for mouse M 1 (NM_007698), M2 (NM_203491), M3 (NM_033269), M4 (NM_007699), and M5 (NM_205783) were used to design primers for PCR amplification. Primer sequences were M1 sense 5=-TGA CAG GCA ACC TGC TGG TGC T-3= and antisense 5=-AAT CAT CAG AGC TGC CCT GCG G-3=; M2 sense 5=-CGG ACC ACA AAA ATG GCA GGC AT-3=and antisense 5=-CCA TCA CCA CCA GGC ATG TTG TTG T-3=; M3 sense 5=-CCT CTT GAA GTG CTG CGT TCT GAC C-3= and antisense 5=-TGC CAG GAA GCC AGT CAA GAA TGC-3=; M4 sense 5=-TGT GGT GAG CAA TGC CTC TGT CAT G-3= and antisense 5=-GGC TTC ATC AGA GGG CTC TTG AGG A-3=; M5 sense 5=-ACC ACT GAC ATA CCG AGC CAA GCG-3= and antisense 5=-TTC CCG TTG TTG AGG TGC TTC TAC G-3=; ␤-actin sense 5=-CAC CCG CGA GCA CAG CTT CTT T-3= and antisense 5=-AAT ACA GCC CGG GGA GCA TC-3=. The expression levels of muscarinic receptor subtype mRNA were normalized to ␤-actin using the ⌬Ct method. Parallelism of standard curves was confirmed.
Vessel preparation. Mice were killed by CO2 inhalation. Next, the kidneys, the hindlimbs, and a proximal segment of the tail were immediately removed and placed in ice-cold Krebs buffer with the following ionic composition (in mmol/l): 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, and 11 glucose. Small cutaneous arteries from the tail (115-267 m internal diameter), arteries from the gracilis muscle (64 -138 m internal diameter), and renal interlobar arteries (62-145 m internal diameter) from M1R Ϫ/Ϫ , M3R Ϫ/Ϫ , M5R Ϫ/Ϫ , and wild-type mice were isolated under an operating microscope, placed in an organ chamber filled with cold Krebs buffer, cannulated on two glass micropipettes, and secured with 10 -0 nylon monofilament suture as described previously (20, 46) . Vessels were pressurized via the micropipettes to 60 mmHg under no-flow conditions using two reservoirs filled with Krebs buffer and imaged using a video camera mounted on an inverted microscope. Video sequences were captured on a personal computer for analysis. The organ chamber was continuously circulated with oxygenated and carbonated Krebs buffer at 37°C and pH 7.4, and arteries were allowed to equilibrate for 30 -40 min before the start of experiments.
Viability of vessels was assessed as satisfactory when at least 50% constriction from resting diameter in response to KCl (100 mmol/l) was achieved.
Protocols. Arteries were preconstricted with the ␣1-adrenergic receptor agonist phenylephrine to 40 -70% of the initial vessel diameter, and cumulative concentration-response curves to acetylcholine (10 Ϫ9 to 10 Ϫ4 mol/l; Sigma-Aldrich, Munich, Germany) and to substance P (10 Ϫ12 to 10 Ϫ9 mol/l; Biotrend, Cologne, Germany), a nonmuscarinic endothelium-dependent vasodilator, were obtained. Responses to acetylcholine (10 Ϫ4 mol/l) were also compared before and after addition of atropine (10 Ϫ5 mol/l; Sigma-Aldrich), a nonselective muscarinic receptor antagonist. Furthermore, responses to the acetylcholine analog carbachol (10 Ϫ4 mol/l; Sigma-Aldrich) and to the endothelium-independent vasodilator sodium nitroprusside (10 Ϫ5 mol/l; Sigma-Aldrich) were tested.
Statistical analysis. Data are presented as means Ϯ SE, and n represents the number of mice per group. Vascular responses are presented as a percentage of change in diameter from the preconstricted diameter. Comparisons among concentration-response curves were made using ANOVA for repeated measurements. One-way ANOVA was used for comparison of mRNA expression levels and to measure for statistical differences among vascular responses to carbachol and to nitroprusside obtained by a single dose application. Post hoc comparisons were performed by Bonferroni's test. For comparisons of vascular responses to acetylcholine before and after atropine treatment, the Wilcoxon signed-rank test was used. A value of P Ͻ 0.05 was defined as significant.
RESULTS
Muscarinic receptor mRNA expression. Using real-time PCR, we quantified mRNA expression of individual muscarinic receptor subtypes in cutaneous, skeletal muscle, and renal interlobar arteries from wild-type mice. In each preparation, mRNA for all five muscarinic receptor subtypes was detected. However, M 3 receptor mRNA was found to be most abundant (Fig. 1) , M5R Ϫ/Ϫ , and wild-type mice that was similar in the three groups (Fig. 2) . In M3R Ϫ/Ϫ mice, however, acetylcholine-induced responses were virtually abolished in arteries from all three vascular regions tested (Fig. 2) .
To examine whether cholinergic responses of arteries were mediated by muscarinic receptors, we tested responses to acetylcholine (10 Ϫ4 mol/l) before and after addition of atropine (10 Ϫ5 mol/l), a nonselective muscarinic receptor blocker. After atropine treatment, responses to acetylcholine were almost completely abolished in all vascular preparations (Fig. 3) .
To exclude the possibility that different responses to acetylcholine were caused by differences in acetylcholinesterase activity in the vascular wall, we tested vascular responses to carbachol (10 Ϫ4 mol/l), another muscarinic receptor agonist that, in contrast to acetylcholine, is resistant to degradation by acetylcholinesterase. Similar to acetylcholine, carbachol induced pronounced vasodilation in cutaneous, skeletal muscle, and renal interlobar arteries from M1R
Ϫ/Ϫ , and wild-type mice that did not differ between these three genotypes (Fig. 4) . In contrast, vasodilation to carbachol was negligible in M3R Ϫ/Ϫ mice (Fig. 4) . Vascular responses to noncholinergic agents. To examine whether deletion of the M 1 , M 3 , or M 5 receptor genes affected vasodilation to a nonmuscarinic endotheliumdependent agonist, we examined responses of cutaneous, skeletal muscle, and renal interlobar arteries from M1R Ϫ/Ϫ , M3R Ϫ/Ϫ , M5R Ϫ/Ϫ , and wild-type mice to substance P (10 Ϫ12 to 10 Ϫ9 mol/l). Substance P elicited concentrationdependent dilatory responses in all three vascular preparations that did not differ between the four mouse genotypes (Fig. 5) . Also, the endothelium-independent NO donor nitroprusside (10 Ϫ5 mol/l) produced vasodilation in arteries from M1R Ϫ/Ϫ , M3R Ϫ/Ϫ , M5R Ϫ/Ϫ , and wild-type mice that did not differ between the four groups (Fig. 6 ).
DISCUSSION
The purpose of the present study was to determine the functional role of M 1 , M 3 , and M 5 acetylcholine receptor subtypes in cutaneous, skeletal muscle, and renal interlobar arteries, all arteries from vascular beds substantially contributing to the control of systemic vascular resistance. Because of the lack of muscarinic agonists and antagonists with pronounced subtype selectivity, we used gene-targeted mice deficient in each of the three receptor subtypes to study vascular function. Remarkably, deletion of the gene coding for the M 3 receptor virtually abolished acetylcholineinduced vasodilation in arteries from all three vascular beds tested. In contrast, neither deletion of the M 1 nor of the M 5 receptor gene significantly affected cholinergic vasodilation. In M3R Ϫ/Ϫ mice, vasodilation of cutaneous, skeletal muscle, and renal interlobar arteries was also negligible in response to the acetylcholine analog carbachol, which is resistant to degradation by acetylcholinesterase. Thus differences in acetylcholinesterase activity in the vascular wall are not likely to contribute to the lack of cholinergic responsiveness of arteries from M3R Ϫ/Ϫ mice. In all three vascular preparations, responses to acetylcholine were almost completely abolished after treatment with the nonselective muscarinic receptor antagonist atropine, indicative of the predominant involvement of muscarinic receptors. Deletion of genes coding for either M 1 , M 3 , or M 5 receptors did not affect vascular responses to the nonmuscarinic endotheliumdependent vasodilator substance P and to the endothelium- 
, and M5R
Ϫ/Ϫ mice, respectively) to acetylcholine. Vasodilation to acetylcholine was negligible in all three preparations from M3R Ϫ/Ϫ mice, whereas deletion of the M1 or M5 receptor gene had no significant effect on acetylcholine-induced responses. *P Ͻ 0.05, M3R
Ϫ/Ϫ vs. all other groups (n ϭ 8 -12/ concentration and genotype).
independent NO donor nitroprusside, suggesting that the absence of these receptors does not interfere with the downstream signaling cascades that ultimately mediate vasorelaxation.
Previous studies of mRNA expression revealed diverse distribution of muscarinic receptor subtypes among vascular beds (34) . Moreover, it has been shown that not all muscarinic receptor subtypes expressed in a specific blood vessel contribute to vasodilation responses (20, 25) . In the present study, we found mRNA for all five muscarinic receptor subtypes in cutaneous, skeletal muscle, and renal interlobar arteries from wild-type mice. Remarkably, in each vascular bed tested, the highest mRNA expression levels were found for the M 3 receptor, in agreement with our findings in functional studies. Disruption of one specific muscarinic receptor gene had only modest effects on the expression pattern of the remaining four receptor subtypes, which is in line with previous studies in nonvascular tissues (44) . Our findings also indicate a lack of functional compensation by other muscarinic receptor subtypes because responses to acetylcholine and carbachol were negligible in mice devoid of the M 3 receptor.
Pharmacological studies making use of subtypepreferring agents as well as functional studies in vascular preparations from muscarinic receptor knockout mice have demonstrated that the M 3 receptor is the predominant mediator of cholinergic vasodilation in coronary and ocular blood vessels (7, 20, 25, 30, 35, 48) . Thus, from a clinical point of view, the M 3 receptor may represent an attractive pharmacological target to modulate cardiac and ocular perfusion. However, before the potential clinical usefulness of this approach can be pursued further, it is important to define the functional role of individual muscarinic receptor subtypes in other vascular resistance beds. So far, only few studies have been performed analyzing muscarinic receptor function in vascular beds substantially contributing to total peripheral resistance. For example, in vivo studies in normo-and hypertensive humans employing receptor subtype-preferring antagonists suggested that cholinergic vasodilation in forearm resistance vessels is mainly mediated by M 3 receptors (5-6). Similar results have been obtained in pharmacological studies in rat isolated perfused kidneys and in mesenteric vascular preparations from rats and mice (14, (21) (22) (23) . Other classical pharmacological studies in the cat middle cerebral artery and in mouse pial arterioles also suggested that M 3 receptors are responsible for cholinergic vasorelaxation in the cerebral circulation (11, 38) . However, the findings in cerebral blood vessels have been challenged by more recent studies reporting that the pharmacological profile of the muscarinic receptor subtype mediating vasodilation in human and bovine cerebral arterioles corresponds best with the M 5 subtype (13) . In agreement with this finding, studies in M 5 receptor-deficient mice demonstrated that responses to acetylcholine were almost completely abolished in pial arterioles and in the basilar artery (46) . Similarly seemingly contradictory results have been reported in other vascular beds. For example, pharmacological experiments in dogs and sheep suggested that cholinergic vasorelaxation in the coronary circulation is mediated by endothelial M 1 receptors (31, 39) . In contrast, studies in various other species, including cattle, horses, monkeys, and mice, have shown that cholinergic dilation of coronary arteries is mediated by M 3 receptors (7, 25, 30, 35) . Likewise, the M 3 receptor was proposed to mediate cholinergic vasodilation in pulmonary arteries from rabbits, rats, and mice (1, 28, 33) . In human pulmonary arteries, however, both M 1 and M 3 receptors were suggested to mediate endothelium-dependent acetylcholine-induced vasorelaxation (29) . Multiple reasons may account for these diverse findings. First, most of the studies were performed in different species. Thus distinct expression and function of muscarinic receptors among species may be one important factor explaining the inconsistent findings. Second, the selectivity of most muscarinic receptor agonists and antagonists is known to be limited. For example, the M 5 receptor shares very similar functional and ligand-binding properties with the M 3 receptor, raising the possibility that responses previously thought to be mediated by M 3 receptors may involve the activation of M 5 receptors (12). Moreover, even "selective" M 1 and M 2 antagonists display high affinity for M 3 and M 4 receptors, respectively (9, 43) . Consequently, it is difficult to study the functional roles of distinct muscarinic receptor subtypes by using pharmacological agents of limited selectivity. This becomes especially apparent when multiple receptor subtypes are simultaneously involved in mediating a specific functional response. These difficulties can be overcome by the use of muscarinic receptor knockout mice, as convincingly demonstrated in the present study.
In conclusion, the results of this study provide the first direct evidence that M 3 receptors mediate cholinergic vasodilation in cutaneous, skeletal muscle, and renal interlobar arteries. Moreover, our findings clearly indicate that neither M 1 nor M 5 receptors participate in acetylcholine-induced vasodilation in the three vascular beds tested, since the absence of both of these receptor subtypes did not affect cholinergic vasodilation.
Perspectives
The present study demonstrates that the M 3 receptor mediates cholinergic vasodilation in small arteries from various vascular resistance beds. Thus drugs activating this receptor subtype may exert hypotensive effects, which supports the findings of a recent study suggesting that M 3 receptor agonists may become beneficial in treating arterial hypertension (49) . In contrast, M 1 and M 5 receptors may represent attractive targets for the selective treatment of local ischemic disorders, since they seem to be functionally relevant in only very few vascular beds. For example, pharmacological activation of M 5 receptors may be useful to increase cerebral perfusion in certain pathophysiological conditions, such as Alzheimer's disease and cerebral ischemia (37, 41) . Interestingly, several agents have been described recently that can selectivity enhance signaling through M 1 or M 5 receptors (4, 8, 27, 40) . Such ligands may become relevant for the development of novel muscarinic drugs aimed at modulating local perfusion. Ϫ/Ϫ mice to substance P. Deletion of either the M1, M3, or the M5 receptor did not affect responses to this endothelium-dependent vasodilator (n ϭ 7-9/concentration and genotype). 
